Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2382377 | 0.70 | TSHR (0.34) | HTTTSHR | |
| SCHEMBL14510164 | 0.70 | CRBN (0.38) | — | |
| SCHEMBL14510166 | 0.70 | CRBN (0.38) | — | |
| SCHEMBL27332551 | 0.70 | CHRM2 (0.33) | — | |
| SCHEMBL8485 | 0.67 | SLC6A2 (0.42) | — | |
| Ammonia Solution, Strong SCHEMBL27469603 | 0.66 | SLC6A2 (0.41) | — | |
| Hydrochloric Acid SCHEMBL12503316 | 0.66 | KDM4E (0.41) | — | |
| Dibenzyl Disulfide SCHEMBL160895 | 0.65 | HSD17B10 (0.52) | TSHRIDO1NOS3NOS1NOS2 | |
| Dibenzyl Disulfide SCHEMBL16332737 | 0.65 | HSD17B10 (0.52) | TSHRIDO1NOS3NOS1NOS2 | |
| SCHEMBL450127 | 0.65 | DRD4 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146540-A1 | Methods of diagnosis and treatment for asthma, allergic rhinitis and other respiratory diseases based on haplotype association | DECODE GENETICS EHF. (IS) | 2008-06-19 | — | — | US | disclosed |
| EP-1848436-A2 | METHODS OF DIAGNOSIS AND TREATMENT FOR ASTHMA, ALLERGIC RHINITIS AND OTHER RESPIRATORY DISEASES BASED ON HAPLOTYPE ASSOCIATION | Decode Genetics EHF. (IS) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006081555-A2 | METHODS OF DIAGNOSIS AND TREATMENT FOR ASTHMA, ALLERGIC RHINITIS AND OTHER RESPIRATORY DISEASES BASED ON HAPLOTYPE ASSOCIATION | DECODE GENETICS EHF. (IS) | 2006-08-03 | — | — | WO | disclosed |
| EP-1646372-A2 | METHODS OF DIAGNOSIS AND TREATMENT FOR ASTHMA BASED ON HAPLOTYPE ASSOCIATION | Decode Genetics EHF. (IS) | 2006-04-19 | — | — | EP | disclosed |
| US-20060014165-A1 | Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association | DECODE GENETICS EHF. (IS) | 2006-01-19 | — | — | US | disclosed |
| WO-2005007144-A2 | METHOD OF DIAGNOSIS AND TREATMENT FOR ASTHMA BASED ON HAPLOTYPE ASSOCIATION | DECODE GENETICS EHF (IS) | 2005-01-27 | — | — | WO | disclosed |
| WO-2003064428-A1 | FURANO- AND THIENOPYRIMIDINES AS NEUROKINASE INHIBITORS | H. LUNDBECK A/S (DK) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146540-A1 | Methods of diagnosis and treatment for asthma, allergic rhinitis and other respiratory diseases based on haplotype association | MAP3K9, MAP4K5, MAP3K19 | HTT 4446/4885TSHR 4297/4885IDO1 417/4885 |
| US-20060014165-A1 | Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association | MAP3K9, MAP3K19, MAP4K5 | HTT 4789/4885TSHR 4512/4885IDO1 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.